Farmas USA

TUSTIN, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals (PPHM) (PPHMP) today announced that two preclinical abstracts and one clinical translation abstract are scheduled for poster presentations at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 18-22, 2015 in Philadelphia, Pennsylvania. Data to be presented include studies investigating the therapeutic potential of Peregrine's phosphatidylserine (PS)-targeting antibodies when administered in combination treatment regimens with approved and developmental cancer immunotherapies and translation data in patients with lung cancer. Peregrine's lead PS-targeting antibody, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications.

Abstract details:

Abstract Number: 274

Presentation Title: Bavituximab modulates tumor microenvironment and activates CD8+ tumor infiltrating lymphocytes in a patient-derived 3D ex vivo system of lung cancer
Presentation Time: Sunday, April 19, 2015, 1:00 PM - 5:00 PM Eastern Daylight Time
Location: Section 13
Poster Board Number: 2
Author Block: Soner Altiok1, Melanie Mediavilla-Valera2, Jenny Kreahling2, David Noyes2, Tiffany N. Razabdouski2, Nikoletta L. Kallinteris3, Joseph Shan3, Scott Antonia2. 1Nilogen Oncosystems, Tampa, FL; 2Moffitt Cancer Center, Tampa, FL; 3Peregrine Pharmaceuticals, Inc, Tustin, CA

Abstract Number: 252

Presentation Title: Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of immune checkpoint blockades in K1735 and B16 mouse melanoma models
Presentation Time: Sunday, April 19, 2015, 1:00 PM - 5:00 PM Eastern Daylight Time
Location: Section 12
Poster Board Number: 10
Author Block: Bruce Freimark1, Jian Gong1, Dan Ye2, Rolf Brekken2, Shen Yin1, Jeff Hutchins1, Van Nguyen1, Chris Hughes3, Xianming Huang2. 1Peregrine Pharmaceuticals, Inc, Tustin, CA; 2UT Southwestern Medical Center, Dallas, TX; 3University of California, Irvine, Irvine, CA

Abstract Number: 4289

Presentation Title: Targeting of phosphatidylserine by monoclonal antibodies enhances the activity of immune checkpoint inhibitors in breast tumors
Presentation Time: Tuesday, April 21, 2015, 1:00 PM - 5:00 PM Eastern Daylight Time
Location: Section 24
Poster Board Number: 19
Author Block: Jian Gong, Shen Yin, Van Nguyen, Jeff Hutchins, Bruce D. Freimark. Peregrine Pharmaceuticals, Inc., Tustin, CA

PPHM

Eleuterio, te paso el grafico de SPHS tal y como lo veo.

Contando con la de hoy llevas dos velas bien ricas, una mas y tienes tu premio.

Si el intento es el de ponerla por encima del dolar pues alla que van PERO si lo que estan haciendo es llevarla a la resistencia de canal la tienes ahi por los 0,98.

De momento, la media movil de 100 dias ha servido de freno. 

Suerte

SPHS

Gracias por el gráfico, en el dolar le pondré un stop, y las dejaré a ver qué hacen. Aunque supongo que llegado el dólar habrán unos picos brutales de subida y bajada, y me saltarán el stop casi seguro. Veremos dónde lo pongo.

SPHS

Madre mía, está a puntito de tocar el dolar !!! +18%

Acabo de quitar mi orden de venta el el dolar, por si acaso.

Vamossss Carlos, trata de arrancarlo por dios, TRATA DE ARRANCARLOOOO!!!!

Yo las largaba en 0,98 o al menos HOY. Si mañana la conferencia no hay nada veras ventas. Pero es solo una opinion, eh? Y no estoy metido en ella ...

SPHS

0,99$ SPHS

ja,ja